Biotech Values

[DewDiligence]

MRK’s hit from ObamaCare is relatively low because MRK does not compete in the antipsychotic market. Antipsychotics have the biggest Medicaid tab of any drug class, and hence they are the most exposed to the higher Medicaid rebates under ObamaCare.